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PURPOSE
• Primaquine (PQ) is primarily used as a
radical cure therapy to eliminate the
relapse of malaria, which is specifically
caused by P. falciparum and P. vivax.
• Limited site-specific delivery of PQ to the
hepatocytes and non-parenchymal cells
and the side-effects associated with its off-
target interactions, effect its clinical
importance.
• Therefore, the current study was
undertaken to design a targeted delivery
system of PQ loaded nanostructured lipid
carrier systems (PQ-NLC) with sterylamine
conjugated lactobionic acid (SALB) for
liver targeting.
CONCLUSION(S)
• SALB anchored PQ-NLC formulations were
successfully developed and optimized with
desirable physicochemical characteristics.
• Further confirmatory studies are needed for
the long-term storage stability and liver




Homogenization followed by probe sonication
method used for the preparation of PQ-NLC-
SALB with varying concentration of SALB as
ligand. Castor oil, Compritol® 888 ATO,
Tween® 80 and Span® 80 were used as
liquid lipid, solid lipid, surfactant, and co-
surfactant, respectively.
Characterization of PQ-NLC-SALB: Particle
size, PDI and zeta potential (ZP) was
measured using Zetasizer, drug content and
entrapment efficiency (EE) was quantified
using HPLC method.
Stability studies: Stability of PQ-NLC-SALB
formulation was observed at refrigerated and
room temperature conditions over one
month.
OBJECTIVE(S)
Designing of targeted delivery system of PQ
loaded nanostructured lipid carrier systems
(PQ-NLC) with SALB (PQ-NLC-SALB) for
liver targeting.
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• Based on initial data, SALB with 0.3% w/v concertation was selected for the preparation of PQ-NLC-SALB formulation.
• PQ-NLC-SALB formulation had 415.4±8.2 nm, 0.3±0.07, -22.4±5.5 mV, 93.4±1.4% and 84.7±0.5% as particle size, PDI,
ZP, assay and EE, respectively.
• PQ-SALB-NLC formulations were found to be stable over one month at refrigerated and room temperature conditions.
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Figure 1: Particle size of PQ-NLC-SALB at refrigerated (RF) 
and room temperature (RT) over one month (mean ± SD, n 
= 3)
Figure 4: EE (%) of PQ-NLC-SALB at refrigerated (RF) and 
room temperature (RT) over one month (mean ± SD, n = 3)
Figure 5: ZP of PQ-NLC-SALB at refrigerated (RF) and room 
temperature (RT) over one month (mean ± SD, n = 3)
Figure 3: PDI of PQ-NLC-SALB at refrigerated (RF) and room 
temperature (RT) over one month (mean ± SD, n = 3)
Figure 2: Assay (%) of PQ-NLC-SALB at refrigerated (RF) and 
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